Navigation Links
Elsevier to Create New Guidelines for Pharmaceutical Article Reprint, Compilation and Custom Publications
Date:6/4/2009

PHILADELPHIA, Pennsylvania, June 4 /PRNewswire-FirstCall/ --

- Company Also Updates Findings Related to Australian Sponsored Publication Practices From 2000-2005

Elsevier, a leading international publisher of scientific, technical and medical (STM) information products and services, announced today it has moved to provide consistent internal guidelines for its pharmaceutical services divisions when producing reprints, article compilations or custom publications on behalf of pharmaceutical companies. This initiative follows an internal review that was commenced when the company became aware of a series of publications produced in Australia between the years 2000 and 2005 that carried the name "journal of" but lacked proper sponsor disclosures and were not in fact journals and should not have been titled as such.

Given the issues identified in the Australasian series, the company is acting to ensure that all of its pharmaceutical services divisions around the globe are following consistent sponsorship practices and disclosure standards for various article reprint products. While these pharmaceutical services divisions frequently reprint peer reviewed articles from Elsevier, they are managed separately from the division that publishes the company's core collection of primary research journals.

Elsevier will review practices related to all article reprint, compilation or custom publications and set out guidelines on content, permission, use of imprint and repackaging to ensure that such publications are not confused with Elsevier's core peer reviewed journals and that the sponsorship of any publication is clearly disclosed. Elsevier expects to complete its review and issue guidelines by June 30, 2009.

"Full disclosure should be the standard at Elsevier, and we need to strive every day to make sure that we enforce consistent global guidelines for sponsorship and disclosure for article reprint products," said Michael Hansen, CEO of Elsevier Health Sciences. "I want to assure our authors, editors, and customers that the integrity of our peer reviewed research journals has not been compromised in any way. These guidelines will help ensure that there is no confusion between these special compilations and our core collection of primary research journals."

Elsevier and other STM publishers each year produce tens of thousands of reprint products (authorized reprints of articles from original primary journals), mostly one or two article reprints with paper covers (compilation products), to more content rich products with reprinted peer reviewed articles and other summaries, abstracts, case studies, conference summaries and glossy covers (custom publications). These products are produced for pharmaceutical companies and serve a valid and useful educational and marketing purpose for these companies.

Update on the Internal Review of Australian Sponsored Journals

Elsevier remains confident the 'Australasian Journal of' series is an isolated practice led by former employees in a local pharmaceutical services division. Within the 'Australasian Journal of' series, the Australasian Journal of Bone and Joint is the only title identified as single sponsored without proper disclosure. An additional eight "Journal of" titles were published with ads from multiple advertisers and therefore did not call for additional disclosure. None of these nine titles were primary research journals and should not have been called journals. An additional 13 'Australasian Journal of' titles were registered to obtain International Standard Serial Number (ISSN) numbers, but were never printed.

Single issues were typically distributed to between 2,000 and 10,000 general practitioners (GP) in Australia, and the company is aware of one issue that went to 20,000 (the estimated total number of GPs in Australia).

Customized and reprint compilation publications, including the 'Australasian Journal of' series are not posted on Science Direct, Elsevier's electronic journal platform for its peer reviewed STM journals. Also, they are not required to be archived or retained.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult ( http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.

Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education, and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK, and ENL (New York Stock Exchange).

    Tom Reller, Director, Corporate Relations, Elsevier
    +1-212-462-1912
    T.Reller@Elsevier.com


'/>"/>
SOURCE Elsevier
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Elseviers PharmaPendium(TM) Introduces the FDA Classic Collection
2. Elseviers PharmaPendium introduces the FDA Classic Collection
3. Elsevier Appoints Chris Dillon as Managing Director, Clinical Decision Support
4. Elsevier launches Epidemics -- the journal on infectious disease dynamics
5. Milestone tumor virus publication by Elsevier journal Virology
6. Elsevier Acquires Professional Development Software, Inc., Provider of Software for Nurses Online Learning Education
7. Elsevier and Brain Mapping Foundation co-host 6th Annual World Congress of IBMISPS
8. Three Prize Winners Awarded in Elseviers Article 2.0 Contest
9. Elsevier Partners With Communispace to Launch Global Online Community
10. Elsevier Announces Launch of Osteopathic Family Physician Publishing Partnership Formed With American College of Osteopathic Family Physicians
11. Elsevier Titles Win Four PROSE Awards From Association of American Publishers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) is pleased ... Building 2. The clinic is the group’s second in New Braunfels and 22nd in ... second New Braunfels location brings things full circle for the group, “It’s crazy to ...
(Date:3/23/2017)... ... ... are unaware of the dangers that infectious bacteria play in mouth disease, while 1 out ... that dentists recommend. The ramifications of improper oral upkeep go far beyond bad breath and ... hours of work each year due to dental issues. That is why Mediaplanet is proud ...
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company announced ... The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive ... that have excellent programs for the delivery and improvement of disease management and ...
(Date:3/23/2017)... ... March 23, 2017 , ... Michael Lanteri Agency, ... greater Fort Collins area, has unveiled a collaboration with nonprofit Big Bones Canine ... to this worthy cause may now be made at http://bigbonescaninerescue.com/ . , ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and ... and Director, AMN Healthcare: Susan Salka , 43rd President of the United States ... Big Fight My Life In and Out of the Ring: Sugar Ray Leonard , ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... March 23, 2017 CENTRO DE IMAGEM DIAGNOSTICOS ... paragraph 4 of Law 6,404/76 and Instruction 358/02 of ... its shareholders and the market in general that it ... Centro de Diagnosticos por Imagem Ltda. (" CDI "), ... in RADIOLOGISTAS ASSOCIADOS LTDA. (" Partnership " and " ...
(Date:3/23/2017)... , March 23, 2017  The goal ... system to identify and track prescription drugs as they ... , in response to requirements from US FDA to ... of potentially dangerous medicines. Blockchain startup ... cryptographic identity chips and blockchain technology and recently raised ...
(Date:3/23/2017)... , March 23, 2017  Cornerstone Pharmaceuticals, ... a major milestone today.  Following successful End-of-Phase ... U.S. Food and Drug Administration (FDA), the ... and regulatory path forward to conduct pivotal ... patients with acute myeloid leukemia (AML) and ...
Breaking Medicine Technology: